/ Sun Pharma Receives US FDA Acceptance Of Biologics License Application For Tildrakizumab ~ Ways2Capital|Stock Tips|Stock Market Tips|Intraday Stock Tips|Stock Trading Tips|NSE BSE Tips

Wednesday, 24 May 2017

Sun Pharmaceuticals Industries, in a BSE filing on Wednesday, has announced the US FDA acceptance of the Biologics License Application (BLA) for tildrakizumab.

The FDA filing acceptance follows the acceptance of the regulatory filing of tildrakizumab by the European Medicines Agency (EMA) in March 2017. Tildrakizumab is an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate-to-severe plaque psoriasis. The BLA filing for tildrakizumab was submitted by Merck & Co., Inc., Kenilworth, NJ, USA, said Sun Pharma.

According to Abhay Gandhi, CEO - North America Business, Sun Pharma, “At Sun Dermatology, we are committed to making a difference in the lives of patients and healthcare providers. The acceptance of the regulatory filing by the U.S. FDA marks a significant milestone as we seek to advance for tildrakizumab as a potential new treatment option for people who continue to struggle everyday with the chronic nature of psoriasis.” Sun Pharmaceuticals Industries was trading down by 0.02% as at 11.44, on Wednesday, on the BSE.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717